ATP6V0D1

Across TCGA pan-cancer cohorts, ATP6V0D1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP6V0D1 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATP6V0D1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATP6V0D1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where ATP6V0D1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.808	1.000	<.001	45	view →
PDAC	OS	Median	IV	0.381	0.951	.006	13	view →
CCRCC	OS	Median	All	0.654	1.000	.010	11	view →
HNSC	DFS	Median	II,III,IV	0.841	0.708	.024	5	view →
GBM	OS	Tertile	All	0.918	0.765	.035	4	view →
LSCC	DFS	Quartile	All	0.825	0.235	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP6V0D1–LUAD (OS)

Open the LUAD breakdown →